Roche Holding AG (RHHBY) Stock Rallies 2.60% Following Positive Phase 3 Kidney Drug Results

TLDR Roche stock jumps 2.60% as Phase 3 kidney drug results boost market momentum. Sefaxersen cuts proteinuria by 43.1% in a pivotal Phase 3 IgA nephropathy trial. Phase 3 data show no new safety signals for Roche’s monthly kidney treatment. More sefaxersen patients see blood in urine resolve than those given a placebo. Roche awaits [...]

The post Roche Holding AG (RHHBY) Stock Rallies 2.60% Following Positive Phase 3 Kidney Drug Results appeared first on Blockonomi.